<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058781</url>
  </required_header>
  <id_info>
    <org_study_id>CER-VD 2016-01232</org_study_id>
    <nct_id>NCT05058781</nct_id>
  </id_info>
  <brief_title>Minipuberty in Infants Born With Potential Hypogonadism Hypogonadotrope</brief_title>
  <acronym>MiniNO</acronym>
  <official_title>Evaluation of Minipuberty in Infants Born With a Variation in Sexual Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disorders of sex development (DSD) occur in 1/3000 births and are defined by variation in&#xD;
      aspect of external genital organs, e.g. cryptorchidism, hypospadias and micropenis in male&#xD;
      infants and clitoral hypertrophy in female infants. Genetic, hormonal and environmental&#xD;
      factors are implicated in DSD. Infants with congenital hypogonadism hypogonadotrope (CHH) can&#xD;
      present with DSD. Evaluation of hormonal profile during minipuberty could be of great help to&#xD;
      better characterize the etiology of DSD and CHH in particular. Our main objective is to study&#xD;
      hormonal profile during the minipuberty of infants born with DSD or born from parents with&#xD;
      CHH compared to controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Years</target_duration>
  <primary_outcome>
    <measure>Hormonal change during minipuberty</measure>
    <time_frame>at 2, 6 and 9 months of age (window for minipuberty)</time_frame>
    <description>measurements of LH, FSH, steroid profile, Testosterone, Estradiol (in girls), AMH, inhibin B in blood and in urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantification of Nitric Oxide metabolites during minipuberty</measure>
    <time_frame>at 2, 6 and 9 months of age</time_frame>
    <description>measurements of Nitrite (NO2-) and nitrate (NO3-) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in expression of genes involved in the NO pathway</measure>
    <time_frame>at birth (if available), 2, 6 and 9 months of age</time_frame>
    <description>RNA sequencing of samples collected in blood</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>DSD</condition>
  <condition>CHH</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, buccal swabs, cord blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All infants born in canton de Vaud in Switzerland&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  infants born with symptoms of DSD&#xD;
&#xD;
          -  infants born from parents with CHH&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  premature &lt; 35 weeks of gestation&#xD;
&#xD;
          -  male infants with high scrotal cryptorchidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>9 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Pitteloud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelly Pitteloud, MD</last_name>
    <phone>+41 79 556 27 36</phone>
    <email>nelly.pitteloud@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Research assistant</last_name>
    <phone>+41 (0)79 556 37 50</phone>
    <email>edm.biobank@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Paccou</last_name>
      <phone>+41 79 556 60 13</phone>
      <email>emmanuelle.paccou@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Argnesa Stojkaj</last_name>
      <phone>+41 79 556 37 50</phone>
      <email>argnesa.stojkaj@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Nelly Pitteloud, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Nelly Pitteloud</investigator_full_name>
    <investigator_title>Professor, Head od Endocrine department</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

